MYLAN TO PAY $30 MILLION FOR DISCLOSURE AND ACCOUNTING FAILURE RELATING TO EPIPEN

The SEC announced charges against Pennsylvania-based pharmaceutical company Mylan N.V. for accounting and disclosure failures rel...


You need to be a subscriber to view this article.

CN Editor

September 30, 2019